The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.
Duke Heart
Shorts
1:03
Heart Failure is a 'Cancer Prognosis' - Why are we ignoring it?
9 months ago
by
Stephen Greene, MD
1:30
Why ARNIs Were Excluded from POLY-HF
a year ago
by
Ambarish Pandey, MD(+2 more)
1:07
POLY-HF's 50% Drop in Heart Failure Hospitalizations
a year ago
by
Muthiah Vaduganathan, MD, MPH(+2 more)
2:14
The Puzzle of Polypill Adherence
a year ago
by
Muthiah Vaduganathan, MD, MPH(+2 more)
1:11
Are Heart Failure Trials Ready for a Major Shift?
a year ago
by
Stephen Greene, MD(+1 more)
1:01
Hospitalizations vs Oral Diuretics as Heart Failure Trial Endpoints
a year ago
by
Muthiah Vaduganathan, MD, MPH(+1 more)
1:49
Why Oral Diuretic Intensification Should Be a Heart Failure Trial Endpoint
a year ago
by
Stephen Greene, MD(+1 more)
1:30
Don't Miss a Beat: Vericiguat and the VICTOR Trial, With Javed Butler, MD
a year ago
by
Muthiah Vaduganathan, MD, MPH(+1 more)
Latest Content
Manesh Patel, MD, discusses the pathophysiology of the relationship between hypercholesterolemia and cardiovascular disease.
The Professor of Medicine at Duke University School of Medicine discusses prescribing DOACs and his opinion on a recent meta-analysis in the Annals of Internal Medicine.
A look back on the biggest discussions of the 29th Annual Cardiovascular Conference in Beaver Creek, CO.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study
4
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
5